Detection of HIV-1 matrix protein p17 quasispecies variants in plasma of chronic HIV-1-infected patients by ultra-deep pyrosequencing

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 3, 2014, Pages 332-339

  Giombini, Emanuela ^a   Dolcetti, Riccardo ^b   Caccuri, Francesca ^c   Selleri, Marina ^a   Rozera, Gabriella ^a   Abbate, Isabella ^a   Bartolini, Barbara ^a   Martorelli, Debora ^b   Faè, Damiana Antonia ^b   Fiorentini, Simona ^c   Giagulli, Cinzia ^c   Capobianchi, Maria R ^a   Caruso, Arnaldo ^c  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Amino acid diversity; COOH terminal region; HIV 1; Matrix protein p17; Quasispecies

Indexed keywords

AMINO ACID; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; MATRIX PROTEIN; PROTEIN P17; VIRUS RNA; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; P17 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; INDEL MUTATION; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PYROSEQUENCING; ULTRA DEEP PYROSEQUENCING; VIRUS GENOME; VIRUS LOAD; YOUNG ADULT; DNA SEQUENCE; GENETIC VARIABILITY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROCEDURES; VIROLOGY;

ADULT; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VARIATION; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84922391873     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000164     Document Type: Article

References (59)

1. Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology. 1998;251:1-15.
2. Gelderblom HR. Assembly and morphology of HIV: potential effect of structure on viral function. AIDS. 1991;5:617-637.
3. Bukrinsky MI, Haggerty S, Dempsey MP, et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature. 1993;365:666-669.
4. Haffar OK, Popov S, Dubrovsky S, et al. Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 preintegration complex. J Mol Biol. 2000;299:359-368.
5. Dalton A, Ako-Adjei D, Murray D, et al. Electrostatic interactions drive membrane association of the human immunodeficiency virus type 1 Gag MA domain. J Virol. 2007;81:6434-6445.
6. Bathia A, Campbell N, Panganiban A, et al. Characterization of replication defects induced by mutations in the basic domain and C-terminus of HIV-1 matrix. Virology. 2007;369:47-54.
7. Facke M, Janetzko A, Shoeman RL, et al. A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum. J Virol. 1993;67:4972-4980.
8. Ono A, Orensein JM, Freed EO. Role of the gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J Virol. 2000;74:2855-2866.
9. Ono A, Freed EO. Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol. 2004;78:1552-1563.
10. Saad JS, Miller J, Tai J, et al. Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci U S A. 2006;103:11364-11369.
11. Alfadhli A, Barklis RL, Barklis E. HIV-1 matrix organizes as a hexamer of trimmers on membranes containing phosphatidylinositol-(4, 5)-biphosphate. Virology. 2009;387:466-472.
12. Freed EO. HIV-1 Gag: flipped out for PI (4, 5) P2. Proc Natl Acad Sci U S A. 2006;103:11101-11102.
13. Davis M, Jiang J, Zhou J, et al. A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of envelope protein subunits gp120 and gp41. J Virol. 2006;80:2405-2417.
14. Pinney JW, Dickerson JE, Fu W, et al. HIV-host interactions: a map of viral perturbation of the host system. AIDS. 2009;23:549-554.
15. Jager S, Cimermancic P, Gulbahce N, et al. Global landscape of HIVhuman protein complexes. Nature. 2011;481:365-370.
16. Casella CR, Raffini LJ, Panganiban AT. Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication. Virology. 1997;228:294-306.
17. Dahiyat BI, Mayo SL. Probing the role of packing specificity in protein design. Proc Natl Acad Sci U S A. 1997;94:10172-10177.
18. Sandberg WS, Terwilliger TC. Influence of interior packing and hydrophobicity on the stability of a protein. Science. 1989;245:54-57.
19. Goh GK, Dunker AK, Uversky VN. A comparative analysis of viral matrix proteins using disorder predictors. Virol J. 2008;5:126.
20. Verli H, Calazans A, Brindeiro R, et al. Molecular dynamics analysis of HIV-1 matrix protein: clarifying differences between crystallographic and solution structures. J Mol Graph Model. 2007;26:62-68.
21. Giagulli C, Marsico S, Magiera AK, et al. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One. 2011;6:e17831.
22. Fiorentini S, Marini E, Caracciolo S, et al. Functions of the HIV-1 matrix protein p17. New Microbiol. 2006;29:1-10.
23. Fiorentini S, Giagulli C, Caccuri F, et al. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS. Pharmacol Ther. 2010;128:433-444.
24. Fiorentini S, Riboldi E, Facchetti F, et al. HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype. Proc Natl Acad Sci U S A. 2008;105:3867-3872.
25. Popovic M, Tenner-racz K, Pelser C, et al. Persistence of structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2005;102:14807-14812.
26. De Francesco MA, Baronio M, Fiorentini S, et al. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci U S A. 2002;99:9972-9977.
27. Vitale M, Caruso A, De Francesco MA, et al. HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines. Br J Haematol. 2003;120:337-343.
28. Marini E, Tiberio L, Caracciolo S, et al. HIV-1 matrix protein p17 binds to monocytes and selectively stimulates MCP-1 secretion: role of transcriptional factor AP-1. Cell Microbiol. 2008;10:655-666.
29. Li S, Bozzo L, Wu Z, et al. The HIV-1 matrix protein p17 activates the transcription factors c-Myc and CREB in human B cells. New Microbiol. 2010;33:13-24.
30. Giagulli C, Magiera AK, Bugatti A, et al. HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation. Blood. 2012;119:2274-2283.
31. Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis. 2002;199:693-701.
32. Abbate I, Vlassi C, Rozera G, et al. Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS. 2011;25:611-617.
33. Kircher M, Kelso J. High-throughput DNA sequencing-concepts and limitations. Bioessays. 2010;32:524-536.
34. Li W, Godzik A. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics. 2006;22:1658-1659.
35. Abbate I, Rozera G, Tommasi C, et al. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clin Microbiol Infect. 2011;17:725-731.
36. Sagar M, Kirkegaard E, Lavreys L, et al. Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res Hum Retroviruses. 2006;22:430-437.
37. Rieder P, Joos B, Scherrer AU, et al. Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clin Infect Dis. 2011;53:1271-1279.
38. Gall A, Kaye S, Hué S, et al. Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters. Retrovirology. 2013;10:8.
39. Swenson LC, Moores A, Low AJ, et al. Improved detection of CXCR4-using HIV by V3 loop genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr. 2010;54:506-510.
40. Rozera G, Abbate I, Bruselles A, et al. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies derived from lympho-monocyte sub-populations. Retrovirology. 2009;12:6-16.
41. Rozera G, Abbate I, Brucelle A, et al. Archived HIV-1 minority variants detected by ultra-deep pyrosequencing in pro virus may be fully replication competent. AIDS. 2009;23:2541-2543.
42. Novitsky V, Wang R, Margolin L, et al. Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection. PLoS One. 2009;4:e7727.
43. Novitsky V, Wang R, Rossenkhan R, et al. Intra-host evolutionary rates in HIV-1C env and gag during primary infection. Infect Genet Evol. 2013;19:361-368.
44. Liang B, Luo M, Scott-Herridge J, et al. A comparison of parallel pyrosequencing and Sanger clone-based sequencing and its impact on the characterization of the genetic diversity of HIV-1. PLoS One. 2011;6:e26745.
45. Abbate I, Cappiello G, Longo R, et al. Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from AIDS patients with neurological disorders. Infect Genet Evol. 2005;5:247-253.
46. Birk M, Flock JI, Sönnerborg A, et al. Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity. AIDS. 1998;12:1973-1981.
47. Chukkapalli V, Oh SJ, Ono A. Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain. Proc Natl Acad Sci U S A. 2010;107:1600-1605.
48. Bugatti A, Giagulli C, Urbinati C, et al. Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparinbinding motif of p17 as a target for the development of multi target antagonists. J Biol Chem. 2013;288:1150-1161.
49. Caccuri F, Giagulli C, Bugatti A, et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A. 2012;105:3867-3872.
50. Fiorentini S, Marsico S, Becker PD, et al. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17. Vaccine. 2008;26:4758-4765.
51. Wain LV, Bailes E, Bibollet-Ruche F, et al. Adaptation of HIV-1 to its human host. Mol Biol Evol. 2007;24:1853-1860.
52. Mwaengo DM, Novembre FJ. Molecular cloning and characterization of viruses isolated from chimpanzees with pathogenic human immunodeficiency virus type 1 infections. J Virol. 1998;72:8976-8987.
53. Bibolet-Ruche F, Heigele A, Keele BF, et al. Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation. J Clin Invest. 1012;122:1644-1652.
54. Dunker AK, Brown CJ, Lawson JD, et al. Intrinsic disorder and protein function. Biochemistry. 2002;41:6573-6582.
55. Uversky VN, Oldfield CJ, Dunker AK. Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. J Mol Recognit. 2005;18:343-384.
56. Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol. 2005;6:197-208.
57. Chargelegue D, Stanley CM, O'Toole CM, et al. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin Exp Immunol. 1995;99:175-181.
58. Binley JM, Klasse PJ, Cao Y, et al. Differential regulation of the antibody response to Gag and Env proteins of human immunodeficiency virus type 1. J Virol. 1997;71:2799-2809.
59. Motozono C, Mwimanzi P, Ueno T. Dynamic interplay between viral adaptation and immune recognition during HIV-1 infection. Protein Cell. 2010;1:514-519.